Skip to search formSkip to main contentSkip to account menu

Dipeptidyl Peptidase-4 Inhibitor

Known as: DPP-4 Inhibitor 
Any inhibitor of the proline-specific serine protease dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. DPP-4 inhibitors bind to DPP-4 and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Renal fibrosis is considered to be the final common outcome of chronic kidney disease. Dipeptidyl peptidase-4 (DPP-4) inhibitors… 
Review
2018
Review
2018
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitor and pioglitazone combination therapy have been widely used for patients with… 
2016
2016
To investigate the relative safety of various glucose‐lowering agents as add‐on medication to metformin in type 2 diabetes in an… 
2013
2013
The pharmacokinetic disposition of anagliptin, an orally active and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor was… 
Highly Cited
2011
Highly Cited
2011
Aim/hypothesis:  To assess the safety and efficacy of initial combination therapy with sitagliptin and pioglitazone compared with… 
2010
2010
Background and ObjectivesLinagliptin (BI 1356) is a highly specific inhibitor of dipeptidyl peptidase (DPP)-4, which is currently… 
Highly Cited
2009
Highly Cited
2009
ABSTRACT Objective: Linagliptin (BI 1356) is a novel, orally available inhibitor of dipeptidyl peptidase-4 (DPP-4). Linagliptin… 
Review
2009
Review
2009
Boehringer Ingelheim Corp is developing the novel, xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor linagliptin for the…